JPRN-UMIN000004482
Completed
未知
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell Carcinoma - Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell Carcinoma
Tokyo Women's Medical University0 sites35 target enrollmentJanuary 15, 2011
ConditionsCytokine refractory Renal cell carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Cytokine refractory Renal cell carcinoma
- Sponsor
- Tokyo Women's Medical University
- Enrollment
- 35
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) No current treatment with any anti\-cancer drugs 2\) No brain metastasis, No hypercalcemia that require medication, No C\-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No current treatment with steroids, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder 3\) Other patients judged to be ineligible by the attending investigators were also excluded from the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I/IIa Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With PSA biochemical failure after radical prostatectomy.JPRN-UMIN000006617Tokyo Women's Medical University10
Recruiting
Not Applicable
A Pilot Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With advanced Renal Cell Carcinomaadvanced Renal cell carcinomaJPRN-UMIN000016793Tokyo Women's Medical University10
Unknown
Phase 1
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
Active, not recruiting
Phase 2
A CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PT 107 (VACCINE) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTSHealth Condition 1: null- Advanced non-small cell lung cancer (Stages IIIB/IV) who have failed first line of chemotherapyCTRI/2010/091/001348PIQUE THERAPEUTICS INC100
Active, not recruiting
Not Applicable
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.EUCTR2004-000838-36-HUPharmexa A/S60